Tom Dineen

1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC

Stefanie S. Schalm, Tom Dineen, Sangbin Lim et al. · Annals of Oncology · 2020 · 50 citations · Full text

Drug Targeting, Medicine, Selective 4Th +6

Screening for lysine-specific demethylase-1 inhibitors using a label-free high-throughput mass spectrometry assay

Matthew Plant, Tom Dineen, Alan C. Cheng et al. · Analytical Biochemistry · 2011 · 34 citations

Medicinal Chemistry, Drug Target, Biochemistry +11

Abstract 1262: BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC

Chiara Conti, John Campbell, Rich Woessner et al. · Cancer Research · 2021 · 24 citations

Metastatic Nsclc, Pathology, Kinase Inhibitors +21

Abstract 1467: BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robust <i>in vivo</i> antitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC)

Sun Min Lim, Chae Won Park, Zhuo Zhang et al. · Cancer Research · 2021 · 17 citations

Lung Adenocarcinoma, Pathology, Abstract 1467 +20

384P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC

Stefanie S. Schalm, Tom Dineen, Sangbin Lim et al. · Annals of Oncology · 2020 · 12 citations · Full text

Drug Targeting, Medicine, Selective 4Th +6